“Gastric Cancer Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastric Cancer Market.

The Gastric Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Gastric Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Gastric Cancer treatment therapies with a considerable amount of success over the years.

• Gastric Cancer companies working in the treatment market are Hubro Therapeutics, Cello Therapeutics, Idience, Leap Therapeutics, Eli Lilly and Company, BeiGene, Hutchison MediPharma, Astellas Pharma, Henlix Biotech, Jiangsu Hengrui Medicine, Neovii Biotech, Genmab/Janssen Biotech, Rapa Therapeutics LLC, HiberCell, Inc., and others, are developing therapies for the Gastric Cancer treatment

• Emerging Gastric Cancer therapies in the different phases of clinical trials are- FMPV-1, CE008, Venadaparib, DKN-01, Abemaciclib, Tislelizumab, Fruquintinib, Zolbetuximab, HLX10, Camrelizumab, Catumaxomab, Amivantamab, RAPA-201, HC 5404 FU, and others are expected to have a significant impact on the Gastric Cancer market in the coming years.

• In October 2026, Perioperative durvalumab plus chemotherapy improves survival: Final Phase III MATTERHORN results, published in September 2026 and highlighted in October, showed that durvalumab plus FLOT chemotherapy significantly improved overall survival in resectable gastric and GEJ adenocarcinoma compared with placebo plus FLOT. The overall-survival hazard ratio was 0.78, indicating a 22% relative reduction in the risk of death

• In September 2026, Evorpacept demonstrates promising activity in HER2-positive gastric cancer: Results from the Phase II portion of ASPEN-06, published in Nature Medicine on September 24, showed that adding investigational evorpacept to trastuzumab, ramucirumab, and paclitaxel increased the objective response rate to 40.3%, compared with 26.6% with the three-drug regimen alone in previously treated advanced gastric/GEJ cancer. The findings support further investigation of CD47 inhibition, particularly in biomarker-selected patients.

• In September 2026, Cadonilimab enters a global Phase III gastric cancer study: On September 28, Akeso announced the first patient enrollment in the COMPASSION-37 trial. The study evaluates cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, in combination with chemotherapy against nivolumab-based or chemotherapy-based control regimens in previously untreated, HER2-negative, unresectable or metastatic gastric/GEJ adenocarcinoma.

• In August 2026, Zanidatamab-based regimens for HER2-positive gastric cancer: On August 25, the FDA approved zanidatamab-hrii (Ziihera) with chemotherapy and tislelizumab-jsgr (Tevimbra) as first-line treatment for adults with HER2-positive, unresectable locally advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma with HER2 IHC 3+ or IHC 2+/ISH-positive disease. The FDA also approved zanidatamab plus chemotherapy without tislelizumab for tumors classified as HER2 IHC 3+.

• In August 2026, ASP2138 advances into Phase III: On August 25, Astellas announced that the first patient had been dosed in a Phase III study of ASP2138 plus chemotherapy and pembrolizumab for first-line treatment of CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric/GEJ adenocarcinoma. The trial plans to enroll approximately 570 participants and assess overall survival and progression-free survival.

• In July 2026, Sonesitatug vedotin shows an overall-survival benefit: On July 27, AstraZeneca announced positive Phase III CLARITY-Gastric01 results for sonesitatug vedotin, an investigational CLDN18.2-targeting antibody-drug conjugate. The trial demonstrated statistically significant improvement in overall survival among patients with advanced gastric/GEJ cancer receiving second- or later-line treatment. The results also showed an overall-survival benefit in the third- or later-line population. Sonesitatug vedotin remains investigational for this indication.

• In March 2025, The FDA awarded orphan drug designation to HLX22, a novel anti-HER2 monoclonal antibody, for the treatment of gastric cancer. This status offers multiple development incentives, such as tax credits for clinical trial expenses, exemption from new drug application fees, and seven years of market exclusivity once approved. These advantages are designed to speed up the development and availability of HLX22, helping patients—especially those with HER2-positive metastatic gastric (GI) or gastroesophageal junction (GEJ) cancer—gain earlier access to this therapy.

• In February 2025, Hanmi Pharmaceutical, based in South Korea, announced favorable results from a Phase I/II clinical trial evaluating Tivumecirnon in combination with MSD’s Keytruda (pembrolizumab) for patients with advanced or metastatic gastric cancer. The study was conducted in collaboration with MSD and RAPT Therapeutics. Tivumecirnon’s development has been a joint effort, with RAPT Therapeutics licensing it to Hanmi in 2019, followed by a clinical collaboration agreement with MSD in 2020.

Gastric Cancer Overview

Gastric cancer, also known as stomach cancer, is a diverse illness that necessitates ongoing study and care in the areas of early detection, prevention, and cutting-edge treatment alternatives. The global distribution of GC varies significantly between geographical regions, demonstrating the wide range of factors that affect the disease’s incidence, survival, and death.

Get a Free Sample PDF Report to know more about Gastric Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/gastric-cancer-pipeline-insight

Emerging Gastric Cancer Drugs Under Different Phases of Clinical Development Include:

• FMPV-1:Hubro Therapeutics

• CE008:Cello Therapeutics

• Venadaparib: Idience

• DKN-01: Leap Therapeutics

• Abemaciclib: Eli Lilly and Company

• Tislelizumab : BeiGene

• Fruquintinib: Hutchison MediPharma

• Zolbetuximab: Astellas Pharma

• HLX10: Henlix Biotech

• Camrelizumab: Jiangsu Hengrui Medicine

• Catumaxomab: Neovii Biotech

• Amivantamab: Genmab/Janssen Biotech

• RAPA-201: Rapa Therapeutics LLC

• HC 5404 FU: HiberCell, Inc.

Gastric Cancer Route of Administration

Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Gastric Cancer Molecule Type

Gastric Cancer Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Gastric Cancer Pipeline Therapeutics Assessment

• Gastric Cancer Assessment by Product Type

• Gastric Cancer By Stage and Product Type

• Gastric Cancer Assessment by Route of Administration

• Gastric Cancer By Stage and Route of Administration

• Gastric Cancer Assessment by Molecule Type

• Gastric Cancer by Stage and Molecule Type

DelveInsight’s Gastric Cancer Report covers around 230+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Gastric Cancer product details are provided in the report. Download the Gastric Cancer pipeline report to learn more about the emerging Gastric Cancer therapies

Some of the key companies in the Gastric Cancer Therapeutics Market include:

Key companies developing therapies for Gastric Cancer are – EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp, and others.

Gastric Cancer Pipeline Analysis:

The Gastric Cancer pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Gastric Cancer with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastric Cancer Treatment.

• Gastric Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Gastric Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastric Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Gastric Cancer drugs and therapies

Gastric Cancer Pipeline Market Drivers

• Increase in the number of patients suffering from Gastric Cancer, increasing awareness about the disease are some of the important factors that are fueling the Gastric Cancer Market.

Gastric Cancer Pipeline Market Barriers

• However, late diagnosis of the Disease, lengthier treatment duration and other factors are creating obstacles in the Gastric Cancer Market growth.

Scope of Gastric Cancer Pipeline Drug Insight

• Coverage: Global

• Key Gastric Cancer Companies: Hubro Therapeutics, Cello Therapeutics, Idience, Leap Therapeutics, Eli Lilly and Company, BeiGene, Hutchison MediPharma, Astellas Pharma, Henlix Biotech, Jiangsu Hengrui Medicine, Neovii Biotech, Genmab/Janssen Biotech, Rapa Therapeutics LLC, HiberCell, Inc., and others

• Key Gastric Cancer Therapies: FMPV-1, CE008, Venadaparib, DKN-01, Abemaciclib, Tislelizumab, Fruquintinib, Zolbetuximab, HLX10, Camrelizumab, Catumaxomab, Amivantamab, RAPA-201, HC 5404 FU, and others

• Gastric Cancer Therapeutic Assessment: Gastric Cancer current marketed and Gastric Cancer emerging therapies

• Gastric Cancer Market Dynamics: Gastric Cancer market drivers and Gastric Cancer market barriers

Request for Sample PDF Report for Gastric Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Gastric Cancer Report Introduction

2. Gastric Cancer Executive Summary

3. Gastric Cancer Overview

4. Gastric Cancer- Analytical Perspective In-depth Commercial Assessment

5. Gastric Cancer Pipeline Therapeutics

6. Gastric Cancer Late Stage Products (Phase II/III)

7. Gastric Cancer Mid Stage Products (Phase II)

8. Gastric Cancer Early Stage Products (Phase I)

9. Gastric Cancer Preclinical Stage Products

10. Gastric Cancer Therapeutics Assessment

11. Gastric Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Gastric Cancer Key Companies

14. Gastric Cancer Key Products

15. Gastric Cancer Unmet Needs

16 . Gastric Cancer Market Drivers and Barriers

17. Gastric Cancer Future Perspectives and Conclusion

18. Gastric Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/